Cargando…

P789: EFFICACY AND SAFETY OF SWITCHING TO IPTACOPAN (IPTA) MONOTHERAPY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATED WITH THE ANTI-C5 MONOCLONAL ANTIBODY (MAB) TESIDOLUMAB (TESI)

Detalles Bibliográficos
Autores principales:	Ando, Kiyoshi, Griškevičius, Laimonas, Ikezoe, Takayuki, Ito, Yoshikazu, Masuko, Masayoshi, Ueda, Yasutaka, Bagger, Morten, Danekula, Rambabu, Rozenberg, Izabela, Junge, Guido, Mayer, Jiri
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430731/ http://dx.doi.org/10.1097/01.HS9.0000970060.17022.e8

Ejemplares similares

Tesidolumab (LFG316) for treatment of C5-variant patients with paroxysmal nocturnal hemoglobinuria
por: Nishimura, Jun-ichi, et al.
Publicado: (2021)

P774: SUBSTANTIAL INCREASES IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) RED BLOOD CELL CLONE SIZE WITH ORAL IPTACOPAN MONOTHERAPY CONFIRMS CONTROL OF HEMOLYSIS IN COMPLEMENT INHIBITOR-NAÏVE PNH PATIENTS
por: Peffault de Latour, Régis, et al.
Publicado: (2023)

S182: ORAL IPTACOPAN MONOTHERAPY INCREASES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) RED BLOOD CELL CLONE SIZE VIA CONTROL OF INTRA- AND EXTRAVASCULAR HEMOLYSIS IN ANTI-C5-TREATED PNH PATIENTS WITH ANEMIA
por: Risitano, Antonio Maria, et al.
Publicado: (2023)

PB2063: APPULSE-PNH: A PHASE IIIB TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF SWITCHING TO IPTACOPAN IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) ON ANTI-C5 THERAPY WITH HEMOGLOBIN >10G/DL
por: Risitano, Antonio Maria, et al.
Publicado: (2023)

Management of paroxysmal nocturnal hemoglobinuria (PNH)
por: Luzzatto, Lucio
Publicado: (2022)

Iptacopan monotherapy in patients with paroxysmal nocturnal hemoglobinuria: a 2-cohort open-label proof-of-concept study
por: Jang, Jun Ho, et al.
Publicado: (2022)

The first successful expanded compassionate use of Iptacopan in a patient with paroxysmal nocturnal hemoglobinuria
por: Han, Bing, et al.
Publicado: (2022)

Autosplenectomy in a Patient with Paroxysmal Nocturnal Hemoglobinuria (PNH)
por: Burns, Ethan, et al.
Publicado: (2019)

Analysis of TET2 mutations in paroxysmal nocturnal hemoglobinuria (PNH)
por: Lobry, Camille, et al.
Publicado: (2019)

Predictive Factors of Mortality in Population of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): Results from a Korean PNH Registry
por: Jang, Jun Ho, et al.
Publicado: (2016)

Baseline clinical characteristics and disease burden in patients with paroxysmal nocturnal hemoglobinuria (PNH): updated analysis from the International PNH Registry
por: Schrezenmeier, Hubert, et al.
Publicado: (2020)

No evidence for hypogammaglobulinemia in patients with paroxysmal nocturnal hemoglobinuria (PNH) chronically treated with ravulizumab
por: Alashkar, Ferras, et al.
Publicado: (2020)

Risk factors for thromboembolic events in patients with paroxysmal nocturnal hemoglobinuria (PNH): a nested case–control study in the International PNH Registry
por: Höchsmann, Britta, et al.
Publicado: (2023)

New Insights in Abdominal Pain in Paroxysmal Nocturnal Hemoglobinuria (PNH): A MRI Study
por: De Cobelli, Francesco, et al.
Publicado: (2015)

Paroxysmal Nocturnal Hemoglobinuria (Pnh): Brain Mri Ischemic Lesions In Neurologically Asymtomatic Patients
por: Barcellini, Wilma, et al.
Publicado: (2018)

Bilateral Multiple Focal Choroidal Excavations in a Patient with Paroxysmal Nocturnal Hemoglobinuria (PNH)
por: Huang, Ping, et al.
Publicado: (2019)

COVID19 infection in a patient undergoing treatment for Paroxysmal Nocturnal Hemoglobinuria (PNH) with Ravulizumab
por: Shikdar, Sufana, et al.
Publicado: (2021)

Relationship of paroxysmal nocturnal hemoglobinuria (PNH) granulocyte clone size to disease burden and risk of major vascular events in untreated patients: results from the International PNH Registry
por: Dingli, David, et al.
Publicado: (2023)

The Role of Whole-Body Magnetic Resonance Imaging (WB-MRI) in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
por: Alashkar, Ferras, et al.
Publicado: (2018)

A novel patient-reported outcome instrument assessing the symptoms of paroxysmal nocturnal hemoglobinuria, the PNH-SQ
por: Daly, R. Paola, et al.
Publicado: (2021)

Popliteal artery thrombosis as a rare complication of paroxysmal nocturnal hemoglobinuria (PNH): A case report
por: Bhusal, Kiran, et al.
Publicado: (2021)

PB2040: LACTATE DEHYDROGENASE IS A PREDICTOR OF THROMBOEMBOLISM, AND THROMBOEMBOLISM IS A PREDICTOR OF DEATH, IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH): RESULTS FROM A KOREAN PNH REGISTRY
por: Jang, Jun Ho, et al.
Publicado: (2023)

Paroxysmal nocturnal hemoglobinuria (PNH): higher sensitivity and validity in diagnosis and serial monitoring by flow cytometric analysis of reticulocytes
por: Höchsmann, Britta, et al.
Publicado: (2011)

Successful pregnancy outcome in paroxysmal nocturnal hemoglobinuria (PNH) following escalated eculizumab dosing to control breakthrough hemolysis
por: Sharma, Ruby, et al.
Publicado: (2015)

Development of a patient-reported outcome questionnaire for aplastic anemia and paroxysmal nocturnal hemoglobinuria (PRO-AA/PNH)
por: Weisshaar, Kimmo, et al.
Publicado: (2020)

Long Non-Coding RNA MALAT1 Contributed to the Proliferation of PNH Clone in Paroxysmal Nocturnal Hemoglobinuria Patients
por: Wang, Honglei, et al.
Publicado: (2021)

Efficacy of eculizumab in paroxysmal nocturnal hemoglobinuria patients with or without aplastic anemia: prospective study of a Korean PNH cohort
por: Choi, Chul Won, et al.
Publicado: (2017)

Assessing Preferences for Rare Disease Treatment: Qualitative Development of the Paroxysmal Nocturnal Hemoglobinuria Patient Preference Questionnaire (PNH-PPQ(©))
por: Kaiser, Karen, et al.
Publicado: (2020)

Characteristics of Taiwanese patients of PNH in the international PNH registry
por: Chou, Wen-Chien, et al.
Publicado: (2016)

Thromboembolic events in patients with paroxysmal nocturnal hemoglobinuria (PNH): Real world data of a Greek nationwide multicenter retrospective study
por: Chatzileontiadou, S., et al.
Publicado: (2023)

IMMUNE LYSIS OF NORMAL HUMAN AND PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) RED BLOOD CELLS : III. THE MEMBRANE DEFECTS CAUSED BY COMPLEMENT LYSIS
por: Rosse, Wendell F., et al.
Publicado: (1966)

Real-World Healthcare Resource Utilization (HRU) and Costs of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Receiving Eculizumab in a US Population
por: Cheng, Wendy Y., et al.
Publicado: (2021)

Complement Inhibition in Paroxysmal Nocturnal Hemoglobinuria (PNH): A Systematic Review and Expert Opinion from Central Europe on Special Patient Populations
por: Bodó, Imre, et al.
Publicado: (2023)

Clinically important change for the FACIT-Fatigue scale in paroxysmal nocturnal hemoglobinuria: a derivation from international PNH registry patient data
por: Cella, David, et al.
Publicado: (2023)

Characteristics of paroxysmal nocturnal hemoglobinuria patients in Brazil: A retrospective administrative claims database analysis of PNH patients in Brazilian public healthcare system
por: Menosi Gualandro, Sandra Fatima, et al.
Publicado: (2023)

Tympanoplasty Outcomes: A Review of 789 Cases
por: Indorewala, Shabbir, et al.
Publicado: (2015)

Association between IPTA Gene Polymorphisms and Hematological Abnormalities in Hepatitis C Virus-Infected Patients Receiving Combination Therapy
por: Hwang, Jow-Jyh, et al.
Publicado: (2015)

Development of a disease-specific quality of life questionnaire for patients with aplastic anemia and/or paroxysmal nocturnal hemoglobinuria (QLQ-AA/PNH)—report on phases I and II
por: Groth, Martha, et al.
Publicado: (2016)

The predictive value of the in vitro platelet toxicity assay (iPTA) for the diagnosis of hypersensitivity reactions to sulfonamides: a case-control study
por: Elzagallaai, Abdelbaset, et al.
Publicado: (2014)

789 Association of food deserts and coronavirus severity in pregnancy
por: Sung, Juliana, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hdbg4admduljfalg90sj4ep88d